BGI Gets CE Mark for EasyNAT SARS-CoV-2 RNA Test

BGI Genomics Co. LTD., announces that its EasyNAT SARS-CoV-2 RNA Test has been CE marked.

It is difficult to differentiate between SARS-CoV-2 and respiratory infections caused by other pathogens through clinical manifestations because of the similar early symptoms. The EasyNAT SARS-CoV-2 RNA Test uses self-driven microfluidic technology to provide rapid and accurate detection of SARS-CoV-2 nucleic acid.

The kit produced by BGI PathoGenesis Pharmaceutical Technology Co., Ltd., a subsidiary of BGI Genomics, is a qualitative in vitro nucleic acid amplification assay to detect SARS-CoV-2 in the specimen of anterior nasal swab from suspect people infected with the virus, like those clustering cases and those under investigation.

The kit especially provides convenience for non-professional laboratories and primary health care institutions to conduct accurate nucleic acid testing, and also expands the application of coronavirus nucleic acid testing.

Share with your community
Quick Contact